These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23247598)

  • 1. Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker.
    Antonelli T; Tomasini MC; Castellazzi M; Sola P; Tamborino C; Ferraro D; Ferraro L; Granieri E
    Neurol Sci; 2013 May; 34(5):769-71. PubMed ID: 23247598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    Trentini A; Castellazzi M; Romani A; Squerzanti M; Baldi E; Caniatti ML; Pugliatti M; Granieri E; Fainardi E; Bellini T; Cervellati C
    J Neurol Sci; 2017 Jun; 377():133-136. PubMed ID: 28477683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kappa Free Light Chains, Soluble Interleukin-2 Receptor, and Interleukin-6 Help Explore Patients Presenting With Brain White Matter Hyperintensities.
    Levraut M; Landes C; Mondot L; Cohen M; Bresch S; Brglez V; Seitz-Polski B; Lebrun-Frenay C
    Front Immunol; 2022; 13():864133. PubMed ID: 35401550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
    Mouzaki A; Rodi M; Dimisianos N; Emmanuil A; Kalavrizioti D; Lagoudaki R; Grigoriadis NC; Papathanasopoulos P
    PLoS One; 2015; 10(8):e0135434. PubMed ID: 26317430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms.
    Fainardi E; Castellazzi M; Casetta I; Cultrera R; Vaghi L; Granieri E; Contini C
    J Neurol Sci; 2004 Feb; 217(2):181-8. PubMed ID: 14706222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylcholinesterase and butyrylcholinesterase activity in the cerebrospinal fluid of patients with neurodegenerative diseases involving cholinergic systems.
    Ruberg M; Villageois A; Bonnet AM; Pillon B; Rieger F; Agid Y
    J Neurol Neurosurg Psychiatry; 1987 May; 50(5):538-43. PubMed ID: 2953866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [CSF acetylcholinesterase activity in central neurological diseases involving cholinergic systems].
    Konagaya M; Konagaya Y; Iida M
    Rinsho Shinkeigaku; 1992 Mar; 32(3):266-71. PubMed ID: 1628449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis.
    Piazza F; DiFrancesco JC; Fusco ML; Corti D; Pirovano L; Frigeni B; Mattavelli L; Andreoni S; Frigo M; Ferrarese C; Tredici G; Cavaletti G
    J Neuroimmunol; 2010 Mar; 220(1-2):104-7. PubMed ID: 20149932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis.
    Romme Christensen J; Börnsen L; Khademi M; Olsson T; Jensen PE; Sørensen PS; Sellebjerg F
    Mult Scler; 2013 Jun; 19(7):877-84. PubMed ID: 23178691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement component C3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis.
    Aeinehband S; Lindblom RP; Al Nimer F; Vijayaraghavan S; Sandholm K; Khademi M; Olsson T; Nilsson B; Ekdahl KN; Darreh-Shori T; Piehl F
    PLoS One; 2015; 10(4):e0122048. PubMed ID: 25835709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid cholinergic biomarkers are associated with postoperative delirium in elderly patients undergoing Total hip/knee replacement: a prospective cohort study.
    Lin X; Tang J; Liu C; Li X; Cao X; Wang B; Dong R; Xu W; Yu X; Wang M; Bi Y
    BMC Anesthesiol; 2020 Sep; 20(1):246. PubMed ID: 32988381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
    Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
    J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
    Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurofilament protein light in multiple sclerosis].
    Zhang Y; Li X; Qiao J
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2745-9. PubMed ID: 18167263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
    Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
    PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Butyrylcholinesterase and Acetylcholinesterase polymorphisms in Multiple Sclerosis patients: implication in peripheral inflammation.
    Reale M; Costantini E; Di Nicola M; D'Angelo C; Franchi S; D'Aurora M; Di Bari M; Orlando V; Galizia S; Ruggieri S; Stuppia L; Gasperini C; Tata AM; Gatta V
    Sci Rep; 2018 Jan; 8(1):1319. PubMed ID: 29358722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques.
    Simone IL; Federico F; Trojano M; Tortorella C; Liguori M; Giannini P; Picciola E; Natile G; Livrea P
    J Neurol Sci; 1996 Dec; 144(1-2):182-90. PubMed ID: 8994122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.